Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03495908 · ClinicalTrials.gov registry record · NA
Regular Insulin vs Rapid Insulin Delivered by V-Go
A NA study, sponsored by East Coast Institute for Research.
- Completed
- Registry status
- NA
- Development phase
- 136
- Enrollment target
NCT03495908: Completed NA study, sponsored by East Coast Institute for Research.
NCT03495908 is a NA study that has completed, run by East Coast Institute for Research. The registered enrollment target is 136 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03495908, a NA study, has completed, sponsored by East Coast Institute for Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of the study is to collect data about how well U-100 Regular Human Insulin can be used in the V-Go Insulin Delivery Device compared to U-100 Rapid Acting Insulin in the V-Go Insulin Delivery Device. The data collected will be used to see how much subjects' blood sugar levels change over time after they switch from using U-100 Rapid Acting Insulin to U-100 Regular Human Insulin within their V-Go Insulin Delivery Device.
Primary Outcome
Per protocol population for assessment of non-inferiority of RHI. Week 12 change from baseline in HbA1c comparison of RHI versus RAI estimated treatment difference.
Interventions
- DEVICE VGo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2019-08-12 |
| Phase | NA |
What the finished NCT03495908 record still lists
NCT03495908 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which VGo is the first listed.
NCT03495908 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03495908 about?
NCT03495908 is a clinical study titled "Regular Insulin vs Rapid Insulin Delivered by V-Go". The purpose of the study is to collect data about how well U-100 Regular Human Insulin can be used in the V-Go Insulin Delivery Device compared to U-100 Rapid Acting Insulin in the V-Go Insulin Delivery Device. The data collected will be used to see how much subjects' blood sugar levels change over ...
What is the current status of trial NCT03495908?
This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2018-04-09. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT03495908?
The interventions under investigation include: VGo (DEVICE).
Who is sponsoring clinical trial NCT03495908?
This trial is sponsored by East Coast Institute for Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03495908's enrollment target sits among peer trials
136 722nd of 2000 higher than 1,275 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI